Comments
Strides Pharma Science on Friday announced that the board of directors of the company has approved an additional investment up to a maximum of $40 million over a period of 24 months for a controlling stake in Stelis Biopharma Private Limited. The proposed new investments will be a primary infusion which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space and also accelerate Strides’ re-entry into sterile injectables business post completion of the company’s non-compete period in December 2019. The stock of Strides Pharma closed 0.18 per cent higher at ₹360 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.